Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TM5614 for SARS-CoV-2 Pneumonia (Phase II, Placebo-Controlled, Double-Blind)
jRCT2021210006Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2021
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and pneumonia comparing TM5614 with Placebo (2 arms). Primary endpoint: Oxygenation Index Scale. Started Jun 2021; status: active, not recruiting.
02
Drugs
TM5614
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on jRCT2021210006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210006.